AstraZeneca backs up Calquence's potential in mantle cell lymphoma with detailed dataAZ reports 27% increase in PFS for Calquence in MCL - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 18, 2024 at 9:44 PM in business No comments 35